You have 9 free searches left this month | for more free features.

myelodysplastic syndrome (MDS)

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

MDS, MDS, Thrombocytopenia Trial (Placebo, Romiplostim)

Completed
  • MDS
  • +2 more
  • Placebo
  • Romiplostim
  • (no location specified)
Nov 4, 2022

MDS, Myeloid Leukemia, Allogeneic Stem Cell Transplantation Trial in Pittsburgh (IFN-? (interferon gamma-1b) injection)

Recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • IFN-γ (interferon gamma-1b) injection
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Jan 5, 2023

MDS, Chronic Myelomonocytic Leukemia Trial in Tianjin (BC3402, Azacitidine)

Recruiting
  • Myelodysplastic Syndromes
  • Chronic Myelomonocytic Leukemia
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital, Chinese Acade
Jul 30, 2023

Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS) Trial in Minneapolis (N-803)

Completed
  • Acute Myelogenous Leukemia (AML)
  • Myelodysplastic Syndrome (MDS)
  • Minneapolis, Minnesota
    Masonic Cancer Center at University of Minnesota
Jan 4, 2023

Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) Trial in Worldwide (HDM201, MBG453, Venetoclax)

Active, not recruiting
  • Acute Myeloid Leukemia (AML)
  • High-risk Myelodysplastic Syndrome (MDS)
  • Durham, North Carolina
  • +8 more
Dec 13, 2022

Myelodysplastic Syndrome (MDS) Trial in Yamagata (ASTX030)

Recruiting
  • Myelodysplastic Syndrome (MDS)
  • Yamagata, Japan
    Yamagata University Hospital
Jun 20, 2022

Myelodysplastic Syndrome Trial in Nagoya, Fukuoka, Tokyo (SyB L-1101)

Completed
  • Myelodysplastic Syndrome
  • SyB L-1101
  • Nagoya, Aichi, Japan
  • +2 more
Nov 14, 2022

Leukemia, Myelodysplastic Syndrome(MDS) Trial in Duarte, Houston (fadraciclib)

Recruiting
  • Leukemia
  • Myelodysplastic Syndrome(MDS)
  • Duarte, California
  • +1 more
Apr 1, 2022

Myelodysplastic Syndrome Trial in Japan (SyB C-1101)

Completed
  • Myelodysplastic Syndrome
  • SyB C-1101
  • Nagoya, Aichi, Japan
  • +3 more
Nov 14, 2022

Relapsed Acute Myeloid Leukemia Trial in Saint Louis (Flotetuzumab, Donor lymphocyte infusion)

Recruiting
  • Relapsed Acute Myeloid Leukemia
  • Saint Louis, Missouri
    Washington University School of Medicine
Sep 7, 2022

MDS Trial in Worldwide (Oral Azacitidine, Placebo for Oral Azacitidine)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Oral Azacitidine
  • Placebo for Oral Azacitidine
  • Buenos Aires, Argentina
  • +1 more
Aug 1, 2022

Leukemia Trial in Houston (Cladribine, Cytarabine, Decitabine)

Recruiting
  • Leukemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Aug 23, 2022

Acute Myeloid Leukemia, MDS Trial (Galinpepimut-S)

Available
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Galinpepimut-S
  • (no location specified)
Oct 20, 2022

Myelodysplastic Syndrome (MDS) Trial in Worldwide (sabatolimab, azacitidine, venetoclax)

Active, not recruiting
  • Myelodysplastic Syndrome (MDS)
  • Brasschaat, Belgium
  • +9 more
Jan 19, 2023

Physical Activity in Transfusion Dependent Myelodysplastic

Recruiting
  • Myelodysplastic Syndromes
  • Medical Device Usage and Evaluation
  • +3 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Aug 16, 2022

MDS, Thrombocytopenia Trial run by the National Heart, Lung, and Blood Institute (NHLBI) (Eltrombopag)

Completed
  • Myelodysplastic Syndromes
  • Thrombocytopenia
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Mar 8, 2022

Severe Aplastic Anemia (SAA), Hypo-Plastic Myelodysplastic Syndrome (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) Trial run

Recruiting
  • Severe Aplastic Anemia (SAA)
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 28, 2023

Acute Myeloid Leukemia, Adult, Myelodysplastic Syndrome(MDS), Allogeneic Hematopoietic Stem Cell Transplantation Trial in Wuhan

Recruiting
  • Acute Myeloid Leukemia, Adult
  • +2 more
  • Fludarabine and Busulfan
  • Fludarabine and Melphalan
  • Wuhan, Hubei, China
    Wuhan Union Hospital, Tongji Medical college, Huazhong Universit
Jan 5, 2023

Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Hematopoietic Stem Cell Transplant (HSCT) Trial in Pittsburgh

Active, not recruiting
  • Acute Myeloid Leukemia (AML)
  • +2 more
  • Reduced-Intensity Conditioning Regimen
  • Myeloablative Conditioning Regimen
  • Pittsburgh, Pennsylvania
    UPMC Children's Hospital of Pittsburgh
Jan 4, 2023

Acute Leukemia, Acute Lymphocytic Leukemia, Acute Myelogenic Leukemia Trial (Haploidentical hematopoietic cell transplantation

Not yet recruiting
  • Acute Leukemia
  • +4 more
  • Haploidentical hematopoietic cell transplantation (haploHCT)
  • matched unrelated donor hematopoietic cell transplantation (MUD-HCT)
  • (no location specified)
Jul 13, 2022

MDS Trial in Houston (Sertraline, Bone Marrow Aspirate/Biopsy)

Terminated
  • Myelodysplastic Syndromes
  • Houston, Texas
  • +1 more
May 31, 2022

Leukemia, Relapsed, Myeloid Trial in Netherlands, Switzerland (MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123

Recruiting
  • Leukemia
  • +3 more
  • MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)
  • Amsterdam, Netherlands
  • +4 more
Jan 4, 2023

AML, Adult Recurrent, MDS Trial in United States (LYT-200)

Recruiting
  • AML, Adult Recurrent
  • MDS
  • Los Angeles, California
  • +13 more
Apr 12, 2023

MDS, Myelodysplastic Anemia, Myelodysplastic Syndrome With Isolated Del(5Q) Trial (description of MDS pzatient cohort)

Recruiting
  • Myelodysplastic Syndromes
  • +5 more
  • description of MDS pzatient cohort
  • Brest, France
    Chu Brest
Oct 27, 2022

MDS Trial in Seoul (cyclophosphamide, fludarabine, and antithymocyte globulin)

Active, not recruiting
  • Myelodysplastic Syndromes
  • cyclophosphamide, fludarabine, and antithymocyte globulin
  • Seoul, Korea, Republic of
    Asan Medical Center, University of Ulsan College of Medicine
Oct 19, 2023